AGAP2

Across TCGA pan-cancer cohorts, AGAP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AGAP2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AGAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where AGAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.793	0.490	.012	9	view →
HNSC	DFS	Tertile	All	0.810	0.309	.031	4	view →
PDAC	OS	Tertile	III,IV	0.344	1.000	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AGAP2–LUAD (DFS)

Open the LUAD breakdown →